Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $58.50

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) has been given an average recommendation of “Hold” by the six ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $58.50.

ANIP has been the subject of a number of research reports. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, March 14th. TheStreet lowered shares of ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Wednesday, March 30th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ANI Pharmaceuticals in a research note on Wednesday, March 16th. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Raymond James decreased their target price on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating for the company in a research note on Wednesday, March 16th.

ANIP stock traded down $0.50 during midday trading on Monday, hitting $29.51. The company’s stock had a trading volume of 87,664 shares, compared to its average volume of 94,243. The company has a market cap of $509.64 million, a PE ratio of -9.08 and a beta of 1.18. ANI Pharmaceuticals has a 12 month low of $24.41 and a 12 month high of $60.23. The company has a current ratio of 3.68, a quick ratio of 2.74 and a debt-to-equity ratio of 0.86. The firm’s 50-day moving average is $31.75 and its 200-day moving average is $39.08.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last released its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.31). The business had revenue of $60.93 million during the quarter, compared to the consensus estimate of $58.25 million. ANI Pharmaceuticals had a negative net margin of 19.71% and a positive return on equity of 14.10%. During the same period last year, the company posted $0.65 earnings per share. Analysts expect that ANI Pharmaceuticals will post 0.62 earnings per share for the current year.

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam purchased 5,000 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was acquired at an average price of $27.65 per share, for a total transaction of $138,250.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Nikhil Lalwani purchased 7,224 shares of the business’s stock in a transaction on Monday, March 21st. The stock was acquired at an average price of $27.69 per share, with a total value of $200,032.56. The disclosure for this purchase can be found here. Insiders bought a total of 17,224 shares of company stock valued at $477,083 over the last 90 days. 27.20% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Emerald Mutual Fund Advisers Trust increased its stake in ANI Pharmaceuticals by 234.7% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 299,493 shares of the specialty pharmaceutical company’s stock worth $8,419,000 after buying an additional 210,002 shares in the last quarter. Emerald Advisers LLC grew its position in shares of ANI Pharmaceuticals by 326.8% during the first quarter. Emerald Advisers LLC now owns 354,045 shares of the specialty pharmaceutical company’s stock valued at $9,952,000 after purchasing an additional 271,101 shares in the last quarter. Comerica Bank grew its position in shares of ANI Pharmaceuticals by 31.1% during the first quarter. Comerica Bank now owns 11,195 shares of the specialty pharmaceutical company’s stock valued at $367,000 after purchasing an additional 2,655 shares in the last quarter. Thompson Siegel & Walmsley LLC grew its position in shares of ANI Pharmaceuticals by 51.7% during the first quarter. Thompson Siegel & Walmsley LLC now owns 424,087 shares of the specialty pharmaceutical company’s stock valued at $11,921,000 after purchasing an additional 144,533 shares in the last quarter. Finally, Collective Family Office LLC grew its position in shares of ANI Pharmaceuticals by 57.4% during the first quarter. Collective Family Office LLC now owns 8,225 shares of the specialty pharmaceutical company’s stock valued at $231,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 53.51% of the company’s stock.

ANI Pharmaceuticals Company Profile (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Recommended Stories

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.